Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name AXL positive
Gene Variant Detail

AXL positive (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
AXL positive Ewing sarcoma sensitive Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited growth of Ewing sarcoma cell lines positive for Axl expression in culture (PMID: 25528764). 25528764
AXL positive head and neck squamous cell carcinoma sensitive Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited proliferation and invasion of head and neck squamous cell carcinoma cell lines positive for Axl expression in culture (PMID: 25767293). 25767293
AXL positive head and neck squamous cell carcinoma sensitive Bemcentinib + Cetuximab Preclinical Actionable In a preclinical study, BGB-324 and Erbitux (cetuximab) worked synergistically to inhibit proliferation of Axl-positive head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293). 25767293
AXL positive breast cancer sensitive Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited tumor growth and metastasis in xenograft models of Axl-positive breast cancer cell lines, resulting in prolonged survival (PMID: 20145120). 20145120
AXL positive triple-receptor negative breast cancer sensitive Dubermatinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, a triple-receptor negative breast cancer cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). 27671334
AXL positive lung non-small cell carcinoma sensitive Dubermatinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, a non-small cell lung carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). 27671334
AXL positive head and neck squamous cell carcinoma sensitive Dubermatinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, a head and neck squamous cell carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). 27671334
AXL positive triple-receptor negative breast cancer sensitive Bemcentinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, an AXL-expressing triple-receptor negative breast cancer cell line demonstrated greater sensitivity to the combination of Bemcentinib (BGB-324) and Lynparza (olaparib) compared to either agent alone in culture, resulting in a highly synergistic effect (PMID: 27671334). 27671334
AXL positive lung non-small cell carcinoma sensitive Bemcentinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, an AXL-expressing non-small cell lung carcinoma cell line demonstrated greater sensitivity to the combination of BGB-324 and Lynparza (olaparib) compared to either agent alone in culture, resulting in a highly synergistic effect (PMID: 27671334). 27671334
AXL positive glioblastoma sensitive BMS-777607 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-777607 inhibited Axl phosphorylation, resulted in decreased viability of glioblastoma multiforme cell lines in culture and in cell line xenograft models (PMID: 26848524). 26848524
AXL positive acute myeloid leukemia sensitive Bemcentinib Phase I Actionable In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in complete response in 12.5% (1/8), partial response in 12.5% (1/8), and stable disease in 37.5% (3/8) of acute myeloid leukemia patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)). detail...
AXL positive myelodysplastic syndrome sensitive Bemcentinib Phase I Actionable In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in stable disease in 100% (3/3) of myelodysplastic syndrome patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)). detail...
AXL positive Advanced Solid Tumor predicted - sensitive Enapotamab vedotin Preclinical - Pdx Actionable In a preclinical study, Enapotamab vedotin (HuMax-Axl-ADC) inhibited tumor growth in solid tumor xenograft models, including induction of tumor regression in solid tumor patient-derived xenograft (PDX) models expressing Axl in a subset of tumor cells (J Clin Onc 2015 33:15_suppl, 3066). detail...
AXL positive triple-receptor negative breast cancer sensitive 20G7-D9 Preclinical - Pdx Actionable In a preclinical study, 20G7-D9 inhibited tumor growth in triple-negative breast cancer cell line xenograft models with high or moderate AXL expression and in AXL-expressing patient-derived xenograft (PDX) models (PMID: 27923843). 27923843
AXL positive chronic myeloid leukemia sensitive AXL CAR-T cells Preclinical - Cell culture Actionable In a preclinical study, treatment with AXL CAR-T cells led to induced death of AXL-expressing chronic myeloid leukemia (CML) cells and did not induce death of AXL-negative CML cells in culture (PMID: 29497107). 29497107
AXL positive lung non-small cell carcinoma unknown INCB081776 Preclinical - Cell line xenograft Actionable In a preclinical study, INCB081776 inhibited Axl phosphorylation in tumor, enhanced anti-tumor immune response, inhibited tumor growth in immunocompetent, but not immunodeficient mouse models of non-small cell lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 3759). detail...
AXL positive triple-receptor negative breast cancer sensitive ADCT-601 Preclinical - Cell line xenograft Actionable In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive triple-negative breast cancer cell line in culture and resulted in complete responses in 4/10, partial responses in 5/10, and tumor-free survival in 4/10 cell line xenograft models (PMID: 35086955). 35086955
AXL positive renal cell carcinoma sensitive ADCT-601 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with ADCT-601 induced DNA interstrand crosslinking and inhibited growth of an AXL-positive renal cell carcinoma cell line in culture and at the highest tested dose resulted in a partial response in 1/8, complete responses in 7/8, and tumor-free survival in 6/8 cell line xenograft models (PMID: 35086955). 35086955
AXL positive pancreatic cancer sensitive ADCT-601 Preclinical - Pdx Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive pancreatic cancer cell line in culture and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 35086955). 35086955
AXL positive esophageal cancer sensitive ADCT-601 Preclinical - Pdx Actionable In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive esophageal cancer cell line in culture and resulted in complete responses in 2/8, partial responses in 5/8, and tumor-free survival in 2/8 patient-derived xenograft (PDX) models (PMID: 35086955). 35086955
AXL positive glioblastoma sensitive ADCT-601 Preclinical - Cell culture Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive glioblastoma cell line in culture (PMID: 35086955). 35086955
AXL positive lung adenocarcinoma sensitive ADCT-601 Preclinical - Cell culture Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive lung adenocarcinoma cell line in culture (PMID: 35086955). 35086955
AXL positive ovary adenocarcinoma sensitive ADCT-601 Preclinical - Cell culture Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive ovarian adenocarcinoma cell line in culture (PMID: 35086955). 35086955
AXL positive lung non-small cell carcinoma sensitive ADCT-601 Preclinical - Cell line xenograft Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive non-small cell lung cancer cell line in culture and inhibited tumor growth and increased survival in a cell line xenograft model (PMID: 35086955). 35086955
AXL positive Advanced Solid Tumor sensitive ER-851 Preclinical - Cell culture Actionable In a preclinical study, ER-851 decreased viability of transformed cells expressing AXL in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 36279567). 36279567